carboplatin + neratinib + paclitaxel

Carboplatin + neratinib + paclitaxel is a combination chemotherapy regimen that combines three distinct agents with complementary mechanisms of action. This combination has been investigated for the treatment of various cancers, particularly HER2-positive breast cancer. Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA-approved for HER2-overexpressing/amplified (HER2+) breast cancer in both the adjuvant and metastatic settings[2]. It works by blocking signaling through the HER2 pathway, which is critical for the growth and survival of HER2+ cancer cells. Paclitaxel is a taxane chemotherapy agent that works by stabilizing microtubules, preventing cell division and leading to cell death. Carboplatin is a platinum-based chemotherapy that forms DNA crosslinks, interfering with DNA replication and transcription. When combined, these agents may provide enhanced anti-tumor activity through their complementary mechanisms of action. The combination has shown promising results in clinical settings, particularly for HER2+ breast cancer patients who have progressed on previous therapies[3].